InvestorsHub Logo

DR5

Followers 10
Posts 1100
Boards Moderated 0
Alias Born 01/05/2018

DR5

Re: None

Tuesday, 09/11/2018 11:17:31 AM

Tuesday, September 11, 2018 11:17:31 AM

Post# of 13601
Hey guys/gals, I noticed in the study design that if HemoStyp is found to be “non-inferior” to SurgiCel as the primary outcome then they will evaluate “superiority” to SurgiCel.
IMO, this is a foregone conclusion and if both endpoints are satisfied, this will be a defining moment for United. We just sit back and enjoy a handsome return on our investment.
GLTA! (Longs)
DR5